Each year thousands of infants are born afflicted with beta-thalassemia. Beta thalassemia is majorly prevalent in people from Mediterranean countries, North Africa, the Middle East, India, Central Asia, South Africa and Southeast Asia.
According to the Thalassemia International Federation, about 200,000 patients with thalassemia major are alive and registered as receiving regular treatment around the world.
Key players, such as Bluebird Bio, Protagonist Therapeutics, Acceleron Pharma, Sangamo Therapeutics, Sanofi, Fulcrum Therapeutics, Orchard Therapeutics and others are proactively working towards strengthening the beta-thalassemia market. The launch of various multiple-stage pipeline products will significantly revolutionize the β-thal market dynamics with the continuous efforts in research and development
For more detailed information visit: https://www.delveinsight.com/blog/beta-thalassemia-market/